![]() The origins of CertisAI™ are rooted in the company’s mission: finding the optimal therapy for every cancer patient, the first time, every time. Prioritizing candidates in compound libraries and/or assessing the value of intellectual property Selecting optimal cancer models for in vitro and in vivo validation studiesĭeveloping stratification strategies for clinical trial patient selection Ranking cancer types most likely to respond to a lead candidateĮlucidating synergistic potential of combinatory therapies Uncovering biological pathway mechanisms of action Identifying biomarkers that are predictive of therapeutic response With CertisAI™, researchers can effectively replace many discovery screening studies with in silico predictions, and save time and money by bringing computer-aided insight to a variety of drug development challenges, such as: Many factors contributing to this “translation gap” in cancer therapeutics could be mitigated by better-informed decision-making early in the development process. Computer models can,” he said.īringing AI Support to Cancer Therapeutics Developmentĭespite great progress in cancer research, fewer than 4% of oncology drugs that enter clinical trials are ultimately approved for use. ![]() These dynamics are what govern tumor response to any given therapy, but the complexity involved is too great for any human to grapple with. “This common approach to precision medicine isn’t capturing the nuance of gene expression levels or the complex interrelationships between multiple genetic features. “When it comes to understanding how to treat a person’s cancer, identifying oncogenic DNA mutations is just scratching the surface,” said Peter Ellman, Certis President and CEO. Unlike common single-biomarker strategies often employed in precision medicine, CertisAI™ uses multivariate machine learning algorithms to capture the nuance of biomarker interactions and bring greater accuracy to predictions of drug efficacy. This pan-cancer solution can accelerate drug discovery and companion diagnostics development. SAN DIEGO-( BUSINESS WIRE)-Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the launch of CertisAI™, a new predictive medicine platform that utilizes big data, statistical algorithms, and machine learning to predict drug efficacy based on gene expression biomarkers.
0 Comments
Leave a Reply. |